Werewolf Therapeutics, Inc. HOWL
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is an oncology drug developer. Its lead program, WTX-124, is in Phase 1 for Immunotherapy-sensitive advanced or metastatic solid tumors (incl. cutaneous melanoma), monotherapy and with pembrolizumab. Its next catalyst on record is WTX-124: Completion of Phase 1/1b clinical trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: WTX-124 — Completion of Phase 1/1b clinical trial (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| WTX-124 (conditionally activated IL-2 INDUKINE) | Advanced/metastatic solid tumors, melanoma (Phase 1/1b) | protein/peptide | Phase 1 |
| WTX-330 (conditionally activated IL-12 INDUKINE) | Selected advanced/metastatic solid tumors (Phase 1b/2, Part A dose and regimen determination) | protein/peptide | Phase 1 |
| WTX-712 (IL-21 INDUKINE) | Refractory solid tumors | protein/peptide | Pre-clinical |
| WTX-518, WTX-921, WTX-1011, WTX-2022 | Preclinical INDUKINE/INDUCER candidates, including T cell engagers | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.